Physician profile
Joseph Asher
NPI 1497216154
$866.72
in general payments reported to CMS, 2019-2025
17 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.89 · 2023: $204 · 2024: $246 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.52 | 2023-2025 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.94 | 2022-2025 | Xifaxan |
| Lilly USA, LLC | $121.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $94.87 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $64.89 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.21 | 2025 | Caplyta |
| Novo Nordisk INC | $31.53 | 2024 | Wegovy |
| Novartis Pharmaceuticals Corporation | $29.49 | 2024-2025 | |
| Glaxosmithkline, LLC. | $27.97 | 2023-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $26.43 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $19.95 | 2023 | Keveyis |
| Lundbeck LLC | $16.73 | 2023 | Rexulti |
| Novavax INC | $16.32 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Teva Pharmaceuticals USA, INC. | $15.22 | 2025 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $14.81 | 2024 | Breztri |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.58 | 2024 | Gemtesa |
| Cequr Corporation | $12.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.